OF
NBIX icon

Optimize Financial’s Neurocrine Biosciences NBIX Stock Holding History

Optimize Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$581K Sell
3,447
-12
-0.3% -$1.78K 0.21% 102
2026
Q1 		$456K Buy
3,459
+476
+16% +$63.2K 0.22% 138
2025
Q4 		$423K Buy
2,983
+40
+1% +$5.79K 0.21% 196
2025
Q3 		$413K Buy
+2,943
New +$399K 0.22% 201
2025
Q1 		– Sell
-1,834
Closed -$250K – 264
2024
Q4 		$250K Buy
+1,834
New +$227K 0.19% 167

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Optimize Financial's NBIX Position: Q2 2026 in Review

Optimize Financial reduced its Neurocrine Biosciences (NBIX) stake by 0.35% in Q2 2026, selling an estimated $1.78K and leaving 3,447 shares worth $581K. The position accounts for 0.21% of the portfolio, ranked #102.

Optimize Financial first reported a position in NBIX in Q4 2024 and has held it in 5 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Optimize Financial held 3,447 shares of Neurocrine Biosciences worth $581K as of Q2 2026.
  • Optimize Financial sold 12 Neurocrine Biosciences shares in Q2 2026, an estimated $1.78K.
  • Neurocrine Biosciences made up 0.21% of Optimize Financial's portfolio in Q2 2026, its #102 holding.
  • Optimize Financial first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 5 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Optimize Financial's 13F filing for Q2 2026, filed 27 Aug 2026.